229 related articles for article (PubMed ID: 19004761)
1. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
Gaertner H; Cerini F; Escola JM; Kuenzi G; Melotti A; Offord R; Rossitto-Borlat I; Nedellec R; Salkowitz J; Gorochov G; Mosier D; Hartley O
Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17706-11. PubMed ID: 19004761
[TBL] [Abstract][Full Text] [Related]
2. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
[TBL] [Abstract][Full Text] [Related]
3. G protein subtype-specific signaling bias in a series of CCR5 chemokine analogs.
Lorenzen E; Ceraudo E; Berchiche YA; Rico CA; Fürstenberg A; Sakmar TP; Huber T
Sci Signal; 2018 Oct; 11(552):. PubMed ID: 30327411
[TBL] [Abstract][Full Text] [Related]
4. Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4.
Gaertner H; Lebeau O; Borlat I; Cerini F; Dufour B; Kuenzi G; Melotti A; Fish RJ; Offord R; Springael JY; Parmentier M; Hartley O
Protein Eng Des Sel; 2008 Feb; 21(2):65-72. PubMed ID: 18178567
[TBL] [Abstract][Full Text] [Related]
5. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.
Jin J; Colin P; Staropoli I; Lima-Fernandes E; Ferret C; Demir A; Rogée S; Hartley O; Randriamampita C; Scott MG; Marullo S; Sauvonnet N; Arenzana-Seisdedos F; Lagane B; Brelot A
J Biol Chem; 2014 Jul; 289(27):19042-52. PubMed ID: 24855645
[TBL] [Abstract][Full Text] [Related]
6. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
Pastore C; Picchio GR; Galimi F; Fish R; Hartley O; Offord RE; Mosier DE
Antimicrob Agents Chemother; 2003 Feb; 47(2):509-17. PubMed ID: 12543651
[TBL] [Abstract][Full Text] [Related]
7. High-Affinity Binding of Chemokine Analogs that Display Ligand Bias at the HIV-1 Coreceptor CCR5.
Rico CA; Berchiche YA; Horioka M; Peeler JC; Lorenzen E; Tian H; Kazmi MA; Fürstenberg A; Gaertner H; Hartley O; Sakmar TP; Huber T
Biophys J; 2019 Sep; 117(5):903-919. PubMed ID: 31421836
[TBL] [Abstract][Full Text] [Related]
8. Semisynthetic analogues of PSC-RANTES, a potent anti-HIV protein.
Gaertner H; Offord R; Botti P; Kuenzi G; Hartley O
Bioconjug Chem; 2008 Feb; 19(2):480-9. PubMed ID: 18179159
[TBL] [Abstract][Full Text] [Related]
9. CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.
Escola JM; Kuenzi G; Gaertner H; Foti M; Hartley O
J Biol Chem; 2010 Dec; 285(53):41772-80. PubMed ID: 21041313
[TBL] [Abstract][Full Text] [Related]
10. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
[TBL] [Abstract][Full Text] [Related]
11. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
[TBL] [Abstract][Full Text] [Related]
12. Endocytosis and recycling of the HIV coreceptor CCR5.
Signoret N; Pelchen-Matthews A; Mack M; Proudfoot AE; Marsh M
J Cell Biol; 2000 Dec; 151(6):1281-94. PubMed ID: 11121442
[TBL] [Abstract][Full Text] [Related]
13. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.
Hartley O; Dorgham K; Perez-Bercoff D; Cerini F; Heimann A; Gaertner H; Offord RE; Pancino G; Debré P; Gorochov G
J Virol; 2003 Jun; 77(12):6637-44. PubMed ID: 12767983
[TBL] [Abstract][Full Text] [Related]
15. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
16. A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.
Cerini F; Gaertner H; Madden K; Tolstorukov I; Brown S; Laukens B; Callewaert N; Harner JC; Oommen AM; Harms JT; Sump AR; Sealock RC; Peterson DJ; Johnson SK; Abramson SB; Meagher M; Offord R; Hartley O
Protein Expr Purif; 2016 Mar; 119():1-10. PubMed ID: 26506568
[TBL] [Abstract][Full Text] [Related]
17. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
Owais M; Arya SK
J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
[TBL] [Abstract][Full Text] [Related]
18. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
19. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.
Trkola A; Paxton WA; Monard SP; Hoxie JA; Siani MA; Thompson DA; Wu L; Mackay CR; Horuk R; Moore JP
J Virol; 1998 Jan; 72(1):396-404. PubMed ID: 9420238
[TBL] [Abstract][Full Text] [Related]
20. Chemokine analogues show suitable stability for development as microbicides.
Cerini F; Landay A; Gichinga C; Lederman MM; Flyckt R; Starks D; Offord RE; Le Gal F; Hartley O
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):472-6. PubMed ID: 18989226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
